Interviews

Part 2: Wayne Winegarden, PhD, on What Canada Can Teach the United States About Biosimilars

September 17, 2020

Video

Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed why importing drugs may not lower costs and what we can learn from Canada’s biosimilar programs.

Part 1: Wayne Winegarden, PhD, on How Employers Can Better Manage Their Formularies

September 15, 2020

Video

Wayne Winegarden, PhD, senior fellow in business and economics at the Pacific Research Institute (PRI) and director of PRI’s Center for Medical Economics and Innovation, discussed where the biosimilar market is heading and how employers can incentivize biosimilar utilization.

Part 2: Brian Gifford on How Treatment Adherence Can Help Employers Save

September 10, 2020

Video

Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed how employers can improve treatment adherence for their employees with rheumatic conditions in order to keep them productive and on the job.

Part 1: Brian Gifford on the Hidden Costs of Rheumatoid Arthritis

September 8, 2020

Video

Brian Gifford, research director of the Integrated Benefits Institute (IBI), discussed employer challenges with managing expenses associated with rheumatoid arthritis and how skillful management of rheumatoid arthritis can keep employees on the job and reduce expense.

Part 2: Surya Singh, MD, on Whether Biosimilars Will Lower Drug Costs

September 3, 2020

Video

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed the future for the US adalimumab market and whether biosimilars can deliver on the promise of lower cost health care.

Part 1: Surya Singh, MD, on Biosimilar Rebates and Payer Decisions

September 2, 2020

Video

Surya Singh, MD, president and owner of Singh Healthcare Advisors LLC in Lexington, Massachusetts, discussed how payers’ decisions regarding formulary lists affect patient out-of-pocket costs and access to biosimilars.

Part 2: Cheryl Larson on What Employers Can Do to Influence Health Plan Decisions

August 27, 2020

Video

Cheryl Larson, president and CEO of the Midwest Business Group on Health, based in Chicago, Illinois, discussed what employers can do to get biosimilars added to their formulary lists and ensure their pharmacy benefit managers (PBMs) aren’t taking advantage of them.

Part 1: Cheryl Larson on How Employers Are Taking on PBMs

August 25, 2020

Video

Cheryl Larson, president and CEO of Midwest Business Group on Health, based in Chicago, Illinois, discussed how some employers are taking on pharmacy benefit managers (PBMs) to get biosimilars added to their formularies and what it could mean for biosimilar savings going forward.

Part 2: Swaminathan P. Iyer, MD, Discusses Changing the Infrastructure of Drug Access

August 20, 2020

Video

Swaminathan P. Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discussed oncology biologics that are too costly for patients whether the Doha Declaration, which would enable governments to license the manufacture of these products, is a viable option.

Part 1: Swaminathan P. Iyer, MD, Discusses Need for Biosimilars in India, US

August 18, 2020

Video

Swaminathan Iyer, MD, a professor of medicine in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center, discussed the importance of biosimilars in India and the United States and the main concerns originator companies have regarding biosimilar competition.

x